Journal
BIOORGANIC CHEMISTRY
Volume 131, Issue -, Pages -Publisher
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.bioorg.2022.106331
Keywords
Antibiotics; LpxC inhibitors; Aldotetronic acid derivatives; Molecular-docking studies; Bacterial uptake; LasB
Ask authors/readers for more resources
To develop inhibitors for bacterial deacetylase LpxC, a series of aldotetronic acid-based hydroxamic acids were synthesized and tested for their inhibitory activity. The most potent inhibitor, benzyl ether 17a, was further evaluated for antibacterial activity, bacterial uptake, and susceptibility to efflux pumps. Molecular docking studies were performed to explain the observed structure-activity relationships.
In order to develop novel inhibitors of the bacterial deacetylase LpxC bearing a substituent to target the UDP binding site of the enzyme, a series of aldotetronic acid-based hydroxamic acids was accessed in chiral pool syntheses starting from 4,6-O-benzylidene-D-glucose and L-arabinitol. The synthesized hydroxamic acids were tested for LpxC inhibitory activity in vitro, revealing benzyl ether 17a ((2S,3S)-4-(benzyloxy)-N,3-dihydroxy-2[(4-{[4-(morpholinomethyl)phenyl]ethynyl}benzyl)oxy]butanamide) as the most potent LpxC inhibitor. This compound was additionally tested for antibacterial activity against a panel of clinically relevant Gram-negative bacteria, bacterial uptake, and susceptibility to efflux pumps. Molecular docking studies were performed to rationalize the observed structure-activity relationships.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available